RET and non-small cell lung carcinoma: On 4 August 2023, Lilly announced topline results from the LIBRETTO-431 study that compared selpercatinib with platinum-based chemotherapy plus pemetrexed, +/− pembrolizumab, as first line treatment for patients RET fusion–positive advanced NSCLC.